Home Journals Articles Updates About
CN
image
收藏切换
Progress of clinical research and application of PCSK9 inhibitors on the management of dyslipidaemias
收藏切换
PDF
Xi Wang1, 2, Jun-Jie Yang2, Yun-Dai Chen2, *
Medical Journal of Chinese People’s Liberation Army | 2022, 47(3) : 292 - 298
Less
收藏切换
Medical Journal of Chinese People’s Liberation Army | 2022, 47(3): 292-298
• Review •
Progress of clinical research and application of PCSK9 inhibitors on the management of dyslipidaemias
Full
Xi Wang1, 2, Jun-Jie Yang2, Yun-Dai Chen2, *
Affiliations
  • 1Medical School of Chinese PLA, Beijing 100853, China
  • 2Department of Cardiovascular Medicine, Chinese PLA General Hospital, Beijing 100048, China
Published: 2022-03-28 doi: 10.11855/j.issn.0577-7402.2022.03.0292
Outline
收藏切换

To strengthen the management of dyslipidaemias in patients with atherosclerotic cardiovascular disease (ASCVD)is regarded as an important measure to delay the disease progression and improve the long-term prognosis. However, there are still a high proportion of domestic patients, whose lipids levels are not up to the standard after receiving conventional lipid lowering therapy, causing an unoptimistic form of lipids management of ASCVD patients in China. As researchers found the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, targeted PCSK9 inhibitors have been put into clinical researches gradually and accumulated series evidence on efficacy and safety. Main literature referred to the clinical research and application progress of PCSK9 inhibitors were reviewed in present paper, to provide a reference for future clinical practice.

coronary artery disease  /  dyslipidaemias  /  proprotein convertase subtilisin/kexin type 9 inhibitors
Xi Wang, Jun-Jie Yang, Yun-Dai Chen. Progress of clinical research and application of PCSK9 inhibitors on the management of dyslipidaemias[J]. Medical Journal of Chinese People’s Liberation Army, 2022 , 47 (3) : 292 -298 . DOI: 10.11855/j.issn.0577-7402.2022.03.0292
Funding
Less
  • National Key Research and Development Program of China(2016YFC1300304)
  • Beijing NOVA Program(Z181100006218055)
Appendix
Less
Year 2022 volume 47 Issue 3
PDF
203
87
Cite this Article
BibTeX
Article Info
doi: 10.11855/j.issn.0577-7402.2022.03.0292
  • Receive Date：2021-08-11
  • Online Date：2025-12-17
  • Published：2022-03-28
Article Data
Affiliations
History
  • Received：2021-08-11
  • Accepted：2021-10-12
Funding
National Key Research and Development Program of China(2016YFC1300304)
Beijing NOVA Program(Z181100006218055)
Affiliations
    1Medical School of Chinese PLA, Beijing 100853, China
    2Department of Cardiovascular Medicine, Chinese PLA General Hospital, Beijing 100048, China

Corresponding:

References
Share
https://castjournals.cast.org.cn/joweb/jfjyxzz/EN/10.11855/j.issn.0577-7402.2022.03.0292
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House